Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Fulgent Genetics, Inc. (FLGT)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/04/2023 |
8-K
| Investor presentation, Quarterly results
Docs:
|
"June 30, December 31, 2023 2022 ASSETS: Cash and cash equivalents $ 58,348 $ 79,506 Investments in marketable securities 788,466 773,377 Accounts receivable, net 34,809 52,749 Property, plant, and equipment, net 87,556 81,353 Other assets 385,398 399,068 Total assets $ 1,354,577 $ 1,386,053 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 91,251 $ 116,178 Total stockholders’ equity 1,263,326 1,269,875 Total liabilities & equity $ 1,354,577 $ 1,386,053 FULGENT GENETICS, INC. Condensed Consolidated Statement of Operations Data Three and Six Months Ended June 30, 2023 and 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 67,853 $ 125,341 $ 134,021 $ 445,609 Cost of revenue 47,281 60,065 94,638 137,790 Gross profit 20,5...",
"2018 2019 2020 2021 2022 2017 2016" |
|
05/05/2023 |
8-K
| Investor presentation, Quarterly results
Docs:
|
"March 31, December 31, 2023 2022 ASSETS: Cash and cash equivalents $ 66,172 $ 79,506 Investments in marketable securities 805,146 773,377 Accounts receivable, net 43,549 52,749 Property, plant, and equipment, net 79,083 81,353 Other assets 382,817 399,068 Total assets $ 1,376,767 $ 1,386,053 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 107,848 $ 116,178 Total stockholders’ equity 1,268,919 1,269,875 Total liabilities & equity $ 1,376,767 $ 1,386,053 FULGENT GENETICS, INC. Condensed Consolidated Statement of Operations Data Three Months Ended March 31, 2023 and 2022 Three Months Ended March 31, 2023 2022 Revenue $ 66,168 $ 320,268 Cost of revenue 47,357 77,725 Gross profit 18,811 242,543 Operating expenses: Research and development 9,782 5,989 Selling...",
"2018 2019 2020 2021 2022 2017 2016" |
|
11/07/2022 |
8-K
| Quarterly results
Docs:
|
"September 30, December 31, 2022 2021 ASSETS: Cash and cash equivalents $ 168,770 $ 164,894 Investments in marketable securities 749,236 770,652 Accounts receivable, net 104,159 138,912 Property, plant, and equipment, net 81,807 62,287 Other assets 301,810 141,975 Total assets $ 1,405,782 $ 1,278,720 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 124,385 $ 112,840 Total stockholders' equity 1,281,397 1,165,880 Total liabilities & equity $ 1,405,782 $ 1,278,720 FULGENT GENETICS, INC. Condensed Consolidated Statement of Income Data Three and Nine Months Ended September 30, 2022 and 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue $ 105,655 $ 227,868 $ 551,264 $ 740,913 Cost of revenue 59,560 43,466 197,350 ...",
"MANY COMPETITORS DO NOT OFFER",
"2018 2019 2020 2021 2022 2017 2016" |
|
08/04/2022 |
8-K
| Quarterly results |
05/03/2022 |
8-K
| Quarterly results |
02/23/2022 |
8-K
| Investor presentation, Quarterly results |
11/09/2021 |
8-K
| Investor presentation, Quarterly results |
08/09/2021 |
8-K
| Investor presentation, Quarterly results |
05/06/2021 |
8-K
| Quarterly results |
03/04/2021 |
8-K
| Quarterly results |
11/09/2020 |
8-K
| Quarterly results |
08/04/2020 |
8-K
| Quarterly results |
05/04/2020 |
8-K
| Quarterly results |
03/10/2020 |
8-K
| Quarterly results |
11/04/2019 |
8-K
| Quarterly results |
08/05/2019 |
8-K
| Quarterly results |
05/07/2019 |
8-K
| Quarterly results |
02/28/2019 |
8-K
| Quarterly results |
11/06/2018 |
8-K
| Quarterly results |
08/06/2018 |
8-K
| Quarterly results |
05/07/2018 |
8-K
| Quarterly results |
02/28/2018 |
8-K
| Quarterly results |
11/06/2017 |
8-K
| Quarterly results |
08/07/2017 |
8-K
| Quarterly results |
05/08/2017 |
8-K
| Form 8-K - Current report |
02/27/2017 |
8-K
| Form 8-K - Current report |
11/03/2016 |
8-K
| Form 8-K - Current report |
|
|